ClinicalTrials.gg
CompletedNCT01508455Updated Aug 23, 2017Results posted

Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age

A Phase 2/3 interventional study of Dexmedetomidine and Midazolam in Anesthesia, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 4 sites in United States. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2017-08-23.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
28 Weeks to 36 Weeks
Sex
All
01

Study summary

The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks through \< 36 weeks gestational age.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.
  2. Age: subjects must fit the following age range at screening:

    Preterm subjects ≥28 weeks through \<36 weeks, gestational age;

    Note: Gestational age (in weeks) will be calculated as follows: the time elapsed between the first day of the last menstrual period and the day of enrollment.

  3. Weight: subject's weight at the time of enrollment must be >1000 g.
  4. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the document approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

Exclusion criteria

Exclusion Criteria:

  1. Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:

    • Diminished consciousness from increased intracranial pressure.
    • The presence of catastrophic brain injury or other severe mental disorders that would make responses to sedatives unpredictable and/or measurement of the N-PASS unreliable.
    • Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking (NMB) agents.
  2. Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires are in situ.

    Note: If subject's status-post Cardio Pulmonary Bypass (CPB) was managed without pacing wires in situ, the subject must not be suspected to be in second degree or third degree heart block at the time of DEX administration.

  3. HR \< 120 bpm prior to the initiation of DEX.
  4. Exposure to any drug within 30 days prior to DEX administration.
  5. Previous exposure to DEX as part of an investigational study.
  6. In subjects that are ex-utero for less than 72 hours, a maternal history of poly-substance drug abuse, based upon the Investigator's clinical judgment.
  7. At the discretion of the Investigator, subjects in whom the risk of DEX treatment is expected to exceed its benefits.
  8. Subjects who have a known allergy or to fentanyl, morphine, MDZ, DEX, or other α-2 agonists.
  9. Requirement for medications other than DEX, MDZ, morphine, or fentanyl for sedation and pain control.
  10. Screening levels >115 U/L.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)

    Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl · Drug: Morphine

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Requiring Rescue Midazolam for Sedation

    Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).

Secondary outcomes

  1. Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion

    Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).

  2. Amount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion

    Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).

  3. Amount of Rescue Medication for Analgesia During DEX Infusion

    Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).

  4. Time Spent With a Total N-PASS Score >3 During DEX Infusion

    The N-PASS score \>3 indicates adequately sedated and not manifesting signs of pain/agitation.

    Time frame: Predose, loading dose (LD) 5 & 10mins/if LD is 20mins (5, 10, 15 & 20mins); maintenance infusion: 0 min, every 15mins (1st hr); every 30mins (2hrs), then hourly; within 5mins of DEX discontinuation; 5mins pre and post rescue medication

  5. Time to Successful Extubation

    Time frame: From the start of study drug infusion to the study completion/withdrawal (Approximately 48 hours)

07

Results

Posted Dec 11, 2013

Participant flow

Neonatal subjects enrolled from 3 centers in the United States

Participant flow — Overall Study
MilestoneDexmedetomidine
Started6
Completed6
Not completed0

Outcome measures

PrimaryPercent of Subjects Requiring Rescue Midazolam for Sedation
Time frame:
During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Reported as:
Number · percentage of participants
Percent of Subjects Requiring Rescue Midazolam for Sedation
percentage of participantsDexmedetomidine
Percent of Subjects Requiring Rescue Midazolam for Sedation0
SecondaryIncidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion
Time frame:
During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Reported as:
Number · participant
Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion
participantDexmedetomidine
Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion1
SecondaryAmount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion
Time frame:
During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).

No measurements were reported for this outcome.

SecondaryAmount of Rescue Medication for Analgesia During DEX Infusion
Time frame:
During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Reported as:
Number · mcg/kg
Amount of Rescue Medication for Analgesia During DEX Infusion
mcg/kgDexmedetomidine
Amount of Rescue Medication for Analgesia During DEX Infusion1
SecondaryTime Spent With a Total N-PASS Score >3 During DEX Infusion

The N-PASS score \>3 indicates adequately sedated and not manifesting signs of pain/agitation.

Time frame:
Predose, loading dose (LD) 5 & 10mins/if LD is 20mins (5, 10, 15 & 20mins); maintenance infusion: 0 min, every 15mins (1st hr); every 30mins (2hrs), then hourly; within 5mins of DEX discontinuation; 5mins pre and post rescue medication
Reported as:
Mean · Hours
Time Spent With a Total N-PASS Score >3 During DEX Infusion
HoursDexmedetomidine
Time Spent With a Total N-PASS Score >3 During DEX Infusion0.44 ± 0.769
SecondaryTime to Successful Extubation
Time frame:
From the start of study drug infusion to the study completion/withdrawal (Approximately 48 hours)
Reported as:
Median · Hours
Time to Successful Extubation
HoursDexmedetomidine
Time to Successful Extubation37.3 (23.083 to 97.833)

Adverse events

Collected over Treatment Emergent Adverse Events. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexmedetomidine—0/6 (0%)3/6 (50%)
Most frequent other events
Most frequent other events
EventDexmedetomidine
Umbilcal herniaGastrointestinal disorders1/6
HypernatraeniaMetabolism and nutrition disorders1/6
BlisterSkin and subcutaneous tissue disorders1/6

Baseline characteristics

All subjects that received study drug.

Age, Categorical
Age, Categorical(Participants)Dexmedetomidine
<=18 years6
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(weeks)Dexmedetomidine
Age Continuous0.8 ± 1.36
Age Continuous: units: Gestational Age32.5 ± 2.74
Sex: Female, Male
Sex: Female, Male(Participants)Dexmedetomidine
Female4
Male2
Region of Enrollment
Region of Enrollment(participants)Dexmedetomidine
United States6
08

Study locations

4 sites
  • Louisville, Kentucky 40202, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Greenville, South Carolina 29605, United States
  • Morgantown, West Virginia 26506, United States
09

References and documents

Publications

  • Chrysostomou C, Schulman SR, Herrera Castellanos M, Cofer BE, Mitra S, da Rocha MG, Wisemandle WA, Gramlich L. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr. 2014 Feb;164(2):276-82.e1-3. doi: 10.1016/j.jpeds.2013.10.002. Epub 2013 Nov 14. PubMed 24238862 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2012
First posted
Jan 12, 2012
Start
Mar 2012
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Dec 11, 2013
Last update
Aug 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01508455
Responsible party
Sponsor
First posted
Jan 12, 2012
Start date
Mar 2012
Primary completion
May 2012
Completion
May 2012
Results posted
Dec 11, 2013
Last update
Aug 23, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion